Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$104.77 USD
-0.47 (-0.45%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $104.41 -0.36 (-0.34%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 481 - 500 ( 534 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
FDA Panel Recommends Tighter TriLipix Label- Vote Is as We Expected.
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term....Several late-stage projects in growing Pharma pipeline to boost longer term growth
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term....Several late-stage projects in growing Pharma pipeline to boost longer term growth
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Big Disconnect: Solid Results Gave No Boost to the Stock
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to be an important growth driver in near to medium term......
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Chinese Pharmaceutical Industry: Fortnightly Update
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to become a more important growth driver in near to medium term
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
4Q Sales Boosted by 23% Pharmaceuticals Growth. EPS Grew at a Double-Digit Rate.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Trimming Our 2011 Projections to Consensus Levels
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Number of late-stage projects in the Pharma pipeline to boost longer term growth.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Sales A Tad Light - High-Quality EPS Beat - Best Gross Margin in At Least a Decade
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Third Quarter EPS Exceeded Expectations. Sales Were a Little Light.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Third Quarter EPS Exceeded Expectations. Sales Were a Little Light
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S